Premium
More questions on buprenorphine and the X‐waiver: What do patients want?
Author(s) -
Knopf Alison
Publication year - 2021
Publication title -
the brown university child and adolescent psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7567
pISSN - 1527-8395
DOI - 10.1002/cpu.30564
Subject(s) - waiver , buprenorphine , opioid use disorder , naltrexone , human services , government (linguistics) , methadone , sign (mathematics) , narcotic antagonists , medicine , political science , psychiatry , opioid , law , (+) naloxone , linguistics , philosophy , receptor , mathematical analysis , mathematics
In the fast‐breaking world of the “X‐waiver” and the imprimatur required by the federal government to prescribe buprenorphine for opioid use disorder (OUD), a recent document (at press time) was a sign‐in letter from an unprecedented coalition of treatment and recovery organizations to the Department of Health and Human Services (HHS) and the Office of National Drug Control Policy (ONDCP) requesting the development of “improved training platforms to replace waiver training prior to waiver elimination.” The Feb. 18 letter, a copy of which was obtained by CPU, supports President Biden's goal of increasing access to the use of methadone, naltrexone, and buprenorphine. It's buprenorphine, however, that is at issue in this letter.